Stacie Calad-Thomson

Chief Operating Officer at ATOM Consortium

Stacie Calad-Thomson is Co-Lead and Chief Operating Officer at the Accelerating Therapeutics for Opportunities in Medicine (ATOM) Consortium, a public-private partnership building AI-driven tools to transform molecular drug design.  Founding consortium members include the Department of Energy’s Lawrence Livermore National Laboratory, GSK, the National Cancer Institute’s Frederick National Laboratory for Cancer Research, and the University of California, San Francisco.  ATOM is developing an active learning platform to accelerate preclinical drug discovery using supercomputing, complex data, and new experimental capabilities.  Stacie has worked for GSK for over 12 years, starting as a chemist and moving into business strategy and operations roles within R&D where she led several change initiatives.  She has a B.S. (UC Berkeley) and a Ph.D. (UC Irvine) in chemistry.